Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 42.25
Bid: 42.00
Ask: 42.50
Change: 0.25 (0.60%)
Spread: 0.50 (1.19%)
Open: 42.25
High: 42.25
Low: 41.20
Prev. Close: 42.00
VLG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UltraDEX update

30 Apr 2018 07:00

RNS Number : 4552M
Venture Life Group PLC
30 April 2018
 

Venture Life Group plc

("Venture Life" or "the Company")

 

UltraDEX update

 

Venture Life (AIM: VLG), the international consumer self-care group focused on developing, manufacturing and commercialising products for the self-care market announces an update on the UltraDEX brand. The Company has extended its agreement with key French distributor La Brosse et Dupont SAS ("La Brosse") to include the UltraDEX Sensitive toothpaste. The launch will take place in H2 2018 and follows the successful launch of the original UltraDEX range in Q1 2018 in France.

 

Founded in 1932, La Brosse is a former subsidiary of LVMH Moet Hennessy Louis Vuitton S.E. It serves customers through large and medium commercial outlets throughout France, including Leclerc and Carrefour, and has market leading products within the oral healthcare space. Le Brosse launched the original UltraDEX range into the French market during March 2018 and is building up a presence in the grocery multiples.

 

UltraDEX was also partnered in Italy and the Nordics in 2017, and after delivery of product in Q4 2017, these partners have also launched UltraDEX into their respective markets during H1 2018. Both partners are building a presence for the mouthwash, toothpaste and spray products in pharmacies and dentists, and early indications are positive for the sell through.

 

Separately, the Company announces the launch of the new UltraDEX 'One GoÔ' range in all 797 of the Superdrug stores in the UK from June 2018. UltraDEX 'One Go' is another new innovative line extension from the Company, providing single use sachets of the UltraDEX mouthwash.

 

Jerry Randall, CEO of Venture Life commented: "The extension of this agreement with La Brosse is a real testament to the continued international success of UltraDEX, particularly at such an early stage in their launch of the UltraDEX range in France. I am delighted with the continued commercial development of the UltraDEX brand both in the UK and internationally, and we look forward updating the market further throughout the rest of the year.

 

"It's also great news that our new product, UltraDEX 'One Go', has been so quickly adopted by one of the leading pharmacy chains, Superdrug, demonstrating our ability to rapidly develop and launch innovative new products into the consumer self-care channel, and we are hopeful to extend its presence further. Innovation is key to the growth of consumer brands, and Venture Life has the experience and capabilities to develop and commercialise such new products."

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).

 

 

 

Enquiries

 

Venture Life Group PLC

+44 (0) 1344 578 004

Jerry Randall, Chief Executive Officer

Adrian Crockett, Chief Financial Officer

 

Northland Capital Partners Limited (Nominated Adviser and Joint Broker)

+44 (0) 20 3861 6625

Matthew Johnson/Edward Hutton (Corporate Finance)

Bob Pountney (Corporate Broking)

Turner Pope Investments (TPI) Ltd (Joint Broker)

+44 (0) 20 3621 4120

Andy Thacker

Walbrook PR

venturelife@walbrookpr.com or +44 (0) 20 7933 8780

Anna Dunphy/Paul McManus

+44 (0) 7876 741 001 / +44 (0) 7980 541 893

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
UPDLLFLESDIDFIT
Date   Source Headline
19th Apr 20247:00 amRNSRCF in Place and New Partner in the USA
9th Apr 20247:00 amRNSFinal Results for year ended 31 December 2023
4th Apr 20247:00 amRNSNotice of Results and Investor Presentation
19th Feb 20245:18 pmRNSHolding(s) in Company
6th Feb 202410:48 amRNSHolding(s) in Company
1st Feb 20247:00 amRNSTrading Update
20th Dec 20232:00 pmRNSHolding(s) in Company
28th Nov 202312:28 pmRNSHolding(s) in Company
22nd Nov 20234:05 pmRNSHolding(s) in Company
14th Nov 20237:00 amRNSChange of Nominated Adviser and Broker
31st Oct 20233:11 pmRNSHolding(s) in Company
17th Oct 20231:54 pmRNSHolding(s) in Company
25th Sep 20237:01 amRNSDirector/PDMR Shareholding
25th Sep 20237:00 amRNSHalf-year Report
5th Sep 20237:00 amRNSInvestor Presentation via Investor Meet Company
31st Jul 20237:00 amRNSTrading Statement
5th Jul 20237:00 amRNSPDMR Shareholdings – Grant of Awards
26th Jun 20234:48 pmRNSDirector/PDMR Shareholding
25th May 20231:54 pmRNSDirector Dealings
22nd May 20233:01 pmRNSResults of AGM
22nd May 20237:00 amRNSAGM Statement
19th May 20237:00 amRNSBoard Change
9th May 20237:00 amRNSNotice of Capital Markets Event
28th Apr 202310:05 amRNSAnnual Report and Notice of AGM
5th Apr 20231:53 pmRNSDirector/PDMR Shareholding
4th Apr 20237:00 amRNSFinal Results for year ended 31 December 2022
31st Mar 20237:00 amRNSInvestor Presentation
13th Mar 20237:00 amRNSUpdate re Revolving Credit Facility
10th Mar 20232:05 pmRNSSecond Price Monitoring Extn
10th Mar 20232:00 pmRNSPrice Monitoring Extension
31st Jan 20237:00 amRNSTrading Statement
9th Jan 20237:00 amRNSLicensing and distribution agreements
1st Dec 20224:41 pmRNSSecond Price Monitoring Extn
1st Dec 20224:37 pmRNSPrice Monitoring Extension
1st Dec 20227:00 amRNSAcquisition and trading update
10th Oct 20227:00 amRNSDirectorate Changes
23rd Sep 202211:08 amRNSInvestor Presentation
22nd Sep 20227:00 amRNSHalf-year Report
25th Jul 202212:00 pmRNSDirector/PDMR Shareholding
25th Jul 20227:00 amRNSTrading Update
20th Jun 20222:31 pmRNSResults of AGM
10th Jun 202212:21 pmRNSDirector/PDMR Shareholding
9th Jun 20225:53 pmRNSAnnual Report & Notice of AGM - Correction
7th Jun 20227:00 amRNSAnnual Report & Notice of AGM
30th May 20224:22 pmRNSDirector/PDMR Shareholding
30th May 20227:00 amRNSDirectorate Changes
23rd May 20224:27 pmRNSHolding(s) in Company
20th May 20227:00 amRNSInvestor Presentation
17th May 20227:00 amRNSDirectorate Changes
17th May 20227:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.